| |
Multivariate analysis
|
|---|
|
HR
|
95% CI
|
p value
|
|---|
|
Training cohort
|
|
GSE31312 (n = 449)
|
|
Age
|
1.03
|
1.01–1.04
|
1.38 × 10−5
|
|
Extra nodal sites number
|
1.20
|
1.03–1.41
|
2.37 × 10−2
|
|
Stage
|
1.31
|
1.12–1.52
|
6.26 × 10−5
|
|
ECOGa
|
1.41
|
1.21–1.64
|
7.33 × 10−6
|
|
Resistance probability of doxorubicin
|
2.70
|
1.24–5.86
|
1.23 × 10−2
|
|
Resistance probability of vincristine
|
1.28
|
0.61–2.70
|
0.51
|
|
Validating cohort
|
|
GSE10846 (n = 342)
|
|
Age
|
1.02
|
1.01–1.04
|
1.45 × 10−4
|
|
Extra nodal sites number
|
0.99
|
0.80–1.22
|
0.95
|
|
Stage
|
1.41
|
1.19–1.67
|
5.40 × 10−5
|
|
ECOGa
|
1.59
|
1.32–1.91
|
6.43 × 10−7
|
|
Resistance probability of doxorubicin
|
3.24
|
1.41–7.45
|
5.61 × 10−3
|
|
Resistance probability of vincristine
|
1.40
|
0.61–3.23
|
0.43
|
- HR hazard ratio, 95% CI 95% confidence interval
- aThe Eastern Cooperative Oncology Group (ECOG) performance score ranges from 0 to 3, with a higher score indicating greater impairment
